A significant downregulation of cyclin D1 was detected in the tumor tissues of different treatment groups (EC/CuNPs, EC/R, and EC/CuNPs/R groups) by − 0.3, − 0.06, and − 0.6 folds, respectively, when compared with untreated tumor group. Here, CCND1 is linked to neoplasm.